Aptamer Group launches £3.75m equity raise to fund AI-enabled discovery and pipeline expansion

Aptamer Group Plc ( (GB:APTA) ) just unveiled an announcement.

Aptamer Group plc has launched an equity fundraising of at least £3.75 million through a placing and direct subscription of new shares at 0.6 pence, alongside a retail offer of up to £0.5 million for existing shareholders at the same price. The transaction, run via an accelerated bookbuild by Turner Pope Investments, will be executed in two tranches because of existing share authority limits, with certain elements contingent on shareholder approval at a forthcoming general meeting.

Investors in the fundraise will receive one warrant for every three new shares subscribed, exercisable over two years at 0.9 pence, creating potential additional equity if the share price appreciates. Net proceeds are earmarked to extend Aptamer’s cash runway to 2028, advance in vivo development of its liver fibrosis delivery vehicle and radiopharmaceutical pipeline, build an AI-enabled Optimer discovery engine for undruggable targets and upgrade manufacturing, which collectively should bolster its technology platform and appeal to EIS and VCT investors.

A separate retail offer via the BookBuild platform is intended to give UK retail shareholders a chance to participate on the same terms as institutions, though completion of this element depends on the success of the placing and subscription. The company has received specialist tax opinions that both the firm and conditional elements of the raise should qualify for EIS and VCT relief, subject to legislative changes and Aptamer maintaining qualifying status, potentially broadening the investor base among tax-efficient capital providers.

The most recent analyst rating on (GB:APTA) stock is a Sell with a £0.62 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.

Spark’s Take on APTA Stock

According to Spark, TipRanks’ AI Analyst, APTA is a Underperform.

The score is primarily held down by very weak financial performance (sharp revenue collapse, continued losses, and negative cash flows). Technical indicators also remain bearish with the stock below major moving averages and negative MACD; oversold momentum readings provide only limited support. Valuation is constrained by a negative P/E and no dividend data.

To see Spark’s full report on APTA stock, click here.

More about Aptamer Group Plc

Aptamer Group plc is a life sciences company that develops next-generation synthetic binders, branded as Optimer, which mimic antibodies by binding to specific biological targets. Its binders are used in therapeutics, diagnostic tests and research tools, aiming to offer higher stability, consistent performance and lower costs than traditional antibodies.

The group operates primarily on a fee-for-service model, supplying custom Optimer binder discovery and development services to biopharma, diagnostics and research clients. Its current strategic focus includes targeted drug delivery platforms and tools for hard-to-drug and undruggable targets, positioning it in advanced biologics and precision medicine markets.

Average Trading Volume: 4,673,444

Technical Sentiment Signal: Sell

Current Market Cap: £18.88M

For detailed information about APTA stock, go to TipRanks’ Stock Analysis page.